Estudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de 2 dosis orales de CP 690,550 y 1 dosis subcutánea de etanercept en sujetos con psoriasis en placas crónica moderada o graveA PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 AND 1 SUBCUTANEOUS DOSE OF ETANERCEPT IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
PHASE II MULTICENTER, PROSPECTIVE, RANDOMIZED, AGE RELATED MACULAR DEGENERATION, COMPARATOR CONTROLLED, DOSE RANGING STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB IN THE TREATMENT OF SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONET STUDY)ESTUDIO EN FASE II MULTICÉNTRICO, PROSPECTIVO, ALEATORIZADO, SOBRE LA DEGENERACIÓN MACULAR ASOCIADA A LA EDAD, CONTROLADO CON TRATAMIENTO ACTIVO Y DE BÚSQUEDA DE DOSIS PARA EVALUAR PF-04523655 FRENTE A RANIBIZUMAB EN EL TRATAMIENTO DE SUJETOS CON NEOVASCULARIZACIÓN COROIDEA (ESTUDIO MONET)
A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN (LYRICA) AND LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES
100 Clinical Results associated with Pfizer SA
0 Patents (Medical) associated with Pfizer SA
100 Deals associated with Pfizer SA
100 Translational Medicine associated with Pfizer SA